These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35795092)

  • 21. Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells.
    DePeaux K; Gunn WG; Rivadeneira DB; Delgoffe GM
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39153823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D; Martuza RL; Rabkin SD
    Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
    Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
    Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
    Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
    Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of fractionated irradiation with anti-VEGF expressing vaccinia virus therapy enhances tumor control by simultaneous radiosensitization of tumor associated endothelium.
    Buckel L; Advani SJ; Frentzen A; Zhang Q; Yu YA; Chen NG; Ehrig K; Stritzker J; Mundt AJ; Szalay AA
    Int J Cancer; 2013 Dec; 133(12):2989-99. PubMed ID: 23729266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [
    Gallegos CA; Lu Y; Clements JC; Song PN; Lynch SE; Mascioni A; Jia F; Hartman YE; Massicano AVF; Houson HA; Lapi SE; Warram JM; Markert JM; Sorace AG
    Theranostics; 2024; 14(3):911-923. PubMed ID: 38250045
    [No Abstract]   [Full Text] [Related]  

  • 28. Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.
    Otani Y; Yoo JY; Shimizu T; Kurozumi K; Date I; Kaur B
    Brain Tumor Pathol; 2022 Apr; 39(2):57-64. PubMed ID: 35384530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
    Wang S; Li Y; Xu C; Dong J; Wei J
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transgenic viral expression of PH-20, IL-12, and sPD1-Fc enhances immune cell infiltration and anti-tumor efficacy of an oncolytic virus.
    Hong SO; Kim J; Lee S; Shin J; Choi H; Lee E; Kang H; Lee H; Lee S; Yun N; An J; Choi H; Kim H; Kang W; Yoon Y; Kim S
    Mol Ther Oncolytics; 2023 Sep; 30():301-315. PubMed ID: 37727704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An oncolytic virus-delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment.
    DePeaux K; Rivadeneira DB; Lontos K; Dean VG; Gunn WG; Watson MJ; Yao T; Wilfahrt D; Hinck C; Wieteska L; Thorne SH; Hinck AP; Delgoffe GM
    J Exp Med; 2023 Oct; 220(10):. PubMed ID: 37552475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
    Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
    Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12.
    Kurokawa C; Agrawal S; Mitra A; Galvani E; Burke S; Varshine A; Rothstein R; Schifferli K; Monks NR; Foloppe J; Silvestre N; Quemeneur E; Demeusoit C; Kleinpeter P; Sapra P; Barrett C; Hammond SA; Kelly EJ; Laliberte J; Durham NM; Oberst M; Broggi MAS
    Mol Ther Oncol; 2024 Mar; 32(1):200758. PubMed ID: 38596304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
    Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
    Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment.
    Nakatake M; Kuwano N; Kaitsurumaru E; Kurosaki H; Nakamura T
    Mol Ther; 2021 May; 29(5):1782-1793. PubMed ID: 33348052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitor boosts anticancer potential of fusogenic oncolytic vaccinia virus by enhancing cell-cell fusion.
    Nakatake M; Kurosaki H; Nakamura T
    Cancer Sci; 2024 Feb; 115(2):600-610. PubMed ID: 38037288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity.
    Seclì L; Infante L; Nocchi L; De Lucia M; Cotugno G; Leoni G; Micarelli E; Garzia I; Avalle L; Sdruscia G; Troise F; Allocca S; Romano G; Scarselli E; D'Alise AM
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37117006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
    Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
    Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.